Literature DB >> 29299798

Mild renal dysfunction defined by creatinine clearance rate has limited impact on clinical outcomes after allogeneic hematopoietic stem cell transplantation.

Shuntaro Ikegawa1, Ken-Ichi Matsuoka2, Tomoko Inomata1, Naoto Ikeda1, Hiroyuki Sugiura1, Taiga Kuroi1, Takeru Asano1, Shohei Yoshida1, Hisakazu Nishimori1, Nobuharu Fujii1, Eisei Kondo1, Yoshinobu Maeda1, Mitsune Tanimoto1.   

Abstract

Creatinine clearance rate (Ccr) is a more accurate indicator of renal function than serum creatinine. Data are sparse regarding the prognostic value of renal impairment calculated using Ccr in patients who undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT). We performed a retrospective analysis of 185 patients who underwent allo-HSCT. These patients were divided into two groups by Ccr (ml/min) before transplantation; one showed normal renal function (Ccr ≥ 60, n = 156) and the other showed mild renal dysfunction (30 ≤ Ccr < 60, n = 29), and transplant outcomes were compared between the groups. We observed no significant difference between the groups in terms of clinical characteristics other than age, estimated glomerular filtration rate, serum creatinine, Ccr predicted by Cockcroft-Gault formula, primary disease, and conditioning intensity. With respect to transplant outcomes, no significant difference was observed in overall survival, relapse, or non-relapse mortality between the two groups. Multivariate analysis demonstrated that 30 ≤ Ccr < 60 before allo-HSCT was not an independent prognostic factor for transplant outcome. In conclusion, these results suggest that patients with mild renal dysfunction, defined as 30 ≤ Ccr < 60 ml/min, can safely undergo allo-HSCT. However, a larger series of patients is needed to evaluate the impact of mild renal dysfunction before allo-HSCT in more detail.

Entities:  

Keywords:  Allogeneic hematopoietic stem cell transplantation; Creatinine clearance rate; Renal dysfunction

Mesh:

Substances:

Year:  2018        PMID: 29299798     DOI: 10.1007/s12185-017-2398-7

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  16 in total

1.  Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences.

Authors:  Mohamed L Sorror; Sergio Giralt; Brenda M Sandmaier; Marcos De Lima; Munir Shahjahan; David G Maloney; H Joachim Deeg; Frederick R Appelbaum; Barry Storer; Rainer Storb
Journal:  Blood       Date:  2007-09-14       Impact factor: 22.113

2.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

3.  Chronic Kidney Disease in Long-Term Survivors after Allogeneic Hematopoietic Stem Cell Transplantation: Retrospective Analysis at a Single Institute.

Authors:  Tomoyasu Jo; Yasuyuki Arai; Tadakazu Kondo; Toshiyuki Kitano; Masakatsu Hishizawa; Kouhei Yamashita; Akifumi Takaori-Kondo
Journal:  Biol Blood Marrow Transplant       Date:  2017-08-16       Impact factor: 5.742

4.  Are the equations for the creatinine-based estimated glomerular filtration rate applicable to the evaluation of renal function in Japanese children and adult patients receiving chemotherapy?

Authors:  Nami Inoue; Hiroyoshi Watanabe; Kazumi Okamura; Shuji Kondo; Shoji Kagami
Journal:  Clin Exp Nephrol       Date:  2014-05-04       Impact factor: 2.801

5.  Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation.

Authors:  Jonas A de Souza; Rima M Saliba; Poliana Patah; Gabriela Rondon; Rachel Ribeiro; Leandro de Padua Silva; Muzaffar H Qazilbash; Chitra Hosing; Uday Popat; Yvonne Efebera; Richard E Champlin; Marcos de Lima
Journal:  Biol Blood Marrow Transplant       Date:  2009-09       Impact factor: 5.742

6.  Early-onset acute kidney injury is a poor prognostic sign for allogeneic SCT recipients.

Authors:  N Shingai; T Morito; Y Najima; T Kobayashi; N Doki; K Kakihana; K Ohashi; M Ando
Journal:  Bone Marrow Transplant       Date:  2015-08-24       Impact factor: 5.483

Review 7.  Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective.

Authors:  Masamitsu Yanada
Journal:  Int J Hematol       Date:  2014-09-12       Impact factor: 2.490

8.  Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.

Authors:  Je-Hwan Lee; Young-Don Joo; Hawk Kim; Hun Mo Ryoo; Min Kyoung Kim; Gyeong-Won Lee; Jung-Hee Lee; Won-Sik Lee; Jae-Hoo Park; Sung-Hwa Bae; Myung Soo Hyun; Dae-Young Kim; Sung-Doo Kim; Young Joo Min; Kyoo-Hyung Lee
Journal:  J Clin Oncol       Date:  2012-11-05       Impact factor: 44.544

Review 9.  1994 Consensus Conference on Acute GVHD Grading.

Authors:  D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas
Journal:  Bone Marrow Transplant       Date:  1995-06       Impact factor: 5.483

10.  Successful outcome after nonmyeloablative allogeneic hematopoietic stem cell transplantation in patients with renal dysfunction.

Authors:  Sabina Kersting; Leo F Verdonck
Journal:  Biol Blood Marrow Transplant       Date:  2008-11       Impact factor: 5.742

View more
  2 in total

1.  Impact of severe acute kidney injury and chronic kidney disease on allogeneic hematopoietic cell transplant recipients: a retrospective single center analysis.

Authors:  Gonzalo Gutiérrez-García; Jesús Villarreal; Marta Garrote; Montserrat Rovira; Miquel Blasco; María Suárez-Lledó; Luis Gerardo Rodríguez-Lobato; Paola Charry; Laura Rosiñol; Pedro Marín; Alexandra Pedraza; María Teresa Solano; Carla Ramos; Noemí de Llobet; Miquel Lozano; Joan Cid; Carmen Martínez; Esteban Poch; Enric Carreras; Álvaro Urbano-Ispizua; Francesc Fernández-Avilés; A Pereira; Luis F Quintana
Journal:  Bone Marrow Transplant       Date:  2020-02-26       Impact factor: 5.483

2.  Effects of Chicory on Serum Uric Acid, Renal Function, and GLUT9 Expression in Hyperuricaemic Rats with Renal Injury and In Vitro Verification with Cells.

Authors:  Yong-Nan Jin; Zhi-Jian Lin; Bing Zhang; Yun-Fei Bai
Journal:  Evid Based Complement Alternat Med       Date:  2018-12-02       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.